(Q35780354)

10 August 2017

1 reference

title

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis (English)

1 reference

10 August 2017

0 references

0 references

Larry W Moreland

1

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

22

1 reference

10 August 2017

issue

2 Suppl 1

1 reference

10 August 2017

page(s)

39-53

1 reference

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Anti-cytokine therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

New therapeutic approaches to the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00005

Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study

1 reference

12 December 2020

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

1 reference

12 December 2020

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis

1 reference

12 December 2020

Fates worse than death: the role of valued life activities in health-state evaluations

1 reference

12 December 2020

10.2165/00019053-200422001-00005

Identifiers

DOI

0 references

Dimensions Publication ID

1038430364

0 references

1 reference